DURABLE GLYCEMIC CONTROL WITH BMF-219 DURING OFF-TREATMENT PERIOD AT WEEK 26: Exhibit 99.2 A PHASE 1/2 TRIAL OF BMF-219 IN PATIENTS WITH TYPE 2 DIABETES (COVALENT-111) 1 2 3 4 5 6 7 7 7 7 7 7 Jose Rodriguez , Alexander Abitbol , Douglas Denham , Rizwana Mohseni , Janice Faulknor , Cesar Perez , Brian Munneke , Courtney Follit , Juan Frias , Sanchita Mourya , Thomas Butler , Steve Morris ; 1 2 3 4 5 6 South West General Healthcare Center, FL, United States of America, LCM Clinical Research, Canada, Clinical Trials of Texas, TX, United States of America, Catalina Research Institute, CA, United States of America, BioPharma Services, Canada, Sunbright Health Medical Center, Clinical Trial Investigator, FL, 7 United States of America, Biomea Fusion, CA, United States of America Background Glycemic Results Summary at Week 26 (22 Weeks After Last Dose of BMF-219) Case Study BMF-219 100mg BMF-219 200mg BMF-219 100mg BMF-219 200mg • T2D is characterized by hyperglycemia due to a progressive decline in beta- Placebo • 51-year-old man with 5-year history of T2D • BMF-219 100mg QD without food for 4 weeks Without Food Without Food With Food With Food N = 6 • Metformin 500mg BID • Metformin continued N = 10 N = 9 N = 10 N = 2 cell function 2 • HbA 8.9%; FPG 184mg/dL; BMI 32.1 kg/m • No adverse events reported 1c Mean change in HbA1c -0.5% -0.1% 0.1% -1.1% 0.3% • Menin, a scaffold protein, is an important regulator of glycemic control, Placebo Adjusted Mean -0.8% -0.4% -0.2% -1.4% -- Change in HbA1c by Study Week CGM Across Study Visits whereby inhibition of menin enhances beta cell proliferation and function Change in HbA1c Percent of Participants with • BMF-219 is an oral covalent menin inhibitor in clinical development for the ≥ 1.0 reduction in HbA1c at 2/10 (20%) 2/9 (22%) 2/10 (20%) 2/2 (100%) 0/6 (0%) Week 26 management of T2D and T1D • In preclinical diabetes ZDF and STZ rat models, BMF-219 showed durable Increase in HOMA-B and C-Peptide at Week 26 1,2 glycemic control following short-term treatment % Change in HOMA-B % Change in C-Peptide • In multiple ascending dose (MAD) cohorts in patients with T2D, 4 weeks of .0 (100mg and 200mg cohorts combined) (100mg and 200mg cohorts combined) BMF-219 100 and 200mg once daily dosing improved glycemic control at Responders* Non-responders Responders* Non-responders 3 Week 26 (22 weeks after the final dose) Aim Week 12 Week 26 Week 4 Baseline Week 12 Week 26 A case study demonstrating continued improvement in HbA1C and improved Time In Range on CGM (after • To assess the safety and efficacy of 4 weeks of once daily BMF-219 at completion of 4 weeks of once daily oral treatment), indicating a durable glycemic control. Week 26 (22 weeks after final dose) Summary and Conclusion Methods • At Week 26 (22 weeks after completion of a 4-week regimen) 100 and 200 mg • COVALENT-111 (NCT05731544) is an ongoing Phase 1/2 randomized, double- N = 8 N = 3 N = 3 N = 17 BMF-219 resulted in: blind, placebo controlled, MAD study evaluating BMF-219 in patients with N = 8 N = 3 inadequately controlled T2D who receive once-daily BMF-219 (50, 100, 200, • Durable glycemic response (≥1.0% HbA1C reduction in 20% and 36% of N = 18 N = 3 patients in once daily 100 and 200mg cohorts, respectively) 400mg) for 4 weeks and are followed until Week 26. • Key eligibility criteria: Adults with T2D treated with up to 3 antidiabetic • Durable increase in C-peptide at Week 26 (22 weeks off treatment) for Placebo Placebo Active Placebo Active Active Active Placebo agents (excluding SU, insulin), HbA1c 7%-10.5%, T2D duration ≤ 15 years BMF-219 responders After 4 weeks of once-daily dosing, responders across both 100 and 200mg cohorts had a greater increase in HOMA-B and • Primary endpoint: Safety and tolerability • Patients who demonstrated the greatest HbA1c reduction at Week 26, had C-peptide AUC when compared to non-responders and placebo. • Secondary endpoints: Measures of glycemic control (HbA1c, CGM), beta cell * Responders have baseline HOMA-B <200 and have achieved at least 0.5% decrease in HbA1c at Week 26 greatest improvement in beta cell function as measured by HOMA-B and function (HOMA-B and C-peptide), and durability of glycemic response C-peptide 200mg Cohorts (N=11) 200mg Cohorts (N=11) Study Design • A generally well tolerated safety profile with no serious adverse events Day 1 BMF-219 Week 4 and no adverse event-related study discontinuations Week 26 (100mg or 200 mg) Daily • No symptomatic or clinically significant hypoglycemia Dosing Period Off-Treatment Period • Robust durable responses seen in many patients after 4 weeks of BMF-219 and Baseline Characteristics and Demographics the demonstration of improvement in beta-cell function which correlates with 100mg without 200mg without 100mg with 200mg with Placebo this glycemic response, support the assessment of longer duration of therapy 1 Characteristics Food Food Food Food (8-12 weeks) with BMF-219 N = 10 N = 10 N = 10 N = 2 N = 6 Age (yrs) 52 (38,63) 50 (25,64) 51 (35,60) 61 (60,61) 46 (31,61) • Subsequent study cohorts are currently assessing BMF-219 administration for Female 4 (40%) 4 (40%) 3 (30%) 2 (100%) 0 (0%) Male 6 (60%) 6 (60%) 7 (70%) 0 (0%) 6 (100%) N = 6 N = 4 N = 3 N = 3 N = 5 N = 6 N = 5 N = 4 up to 12 weeks, with follow-up until Week 52 Duration of diabetes (yrs) 4.3 (0.3,9.3) 4.9 (0.5,11.7) 8.3 (2.6,13.6) 11.3 (9.7,12.8) 3.9 (0.7,9.5) Baseline HbA1c (%) 8.1 (0.92) 7.85 (0.82) 7.96 (0.62) 8.35 (0.64) 8.25 (0.71) Any Decrease in Any Decrease At least 0.5% At least 0.5% Any Decrease in Any Decrease in At least 0.5% At least 0.5% Baseline therapy HbA1c in HbA1c and decrease in Decrease and HbA1c HbA1c and decrease in Decrease and References Baseline HbA1c Baseline Baseline HbA1c Baseline Metformin only 9 (90%) 6 (60%) 5 (50%) 0 (0%) 5 (83%) HOMA-B* <200 HOMA-B* <200 HOMA-B* <200 HOMA-B* <200 Other 1 (10%) 2 (20%) 4 (40%) 2 (100%) 1 (17%) 1. Butler T. et al. Oral Long-Acting Menin Inhibitor Normalizes Type 2 Diabetes Mellitus (T2DM) in Two Rat Models. Diabetes 1 June 2022; 71 (Supplement_1): 851–P. 2. Somanath P. et al. Oral Menin Inhibitor, BMF-219, Displays a Significant and Durable Reduction in HbA1c in a Type 2 Diabetes Mellitus Rat Model. Diabetes 1 June 2022; None 0 (0%) 2 (20%) 1 (10%) 0 (0%) 0 (0%) HOMA-B and C-peptide at Week 26 increases with magnitude of reduction in HbA1C and in patients with baseline HOMA-B <200 71 (Supplement_1): 113–LB. 1 with BMF-219 200 mg once daily dosing for 4 weeks. Mean (Minimum, Maximum); n (%); Mean (SD) 3. Frias J. et al. BMF-219: A Novel Therapeutic Agent to Re-Establish Functional Beta Cells and Provide Long-Term Glycemic Control. Metabolism May 2023; 142 (Supplement): Abstract#0088 * HOMA-B <200 is considered beta cell deficient Mean % Change in HOMA-B Mean % Change in HOMA-B Mean % Change in C-Peptide AUC Mean % Change in C-Peptide AUC Change in HbA1c (%) % Time in Glucose Range
